- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 142
- States / cities
- Anchorage, Alaska • Bakersfield, California • Irvine, California + 117 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2281–2304
of 17,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Enfuvirtide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
- Conditions
- Unresectable Pleural Mesothelioma
- Interventions
- Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 863 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Santa Rosa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
- Conditions
- Suicide Prevention
- Interventions
- Caring Contacts Text Messages
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Disease, Pulmonary Hypertension
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Wrinkle
- Interventions
- GAL1906
- Device
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 22 Years and older · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redondo Beach, California + 11 more
- Conditions
- Diabetes Mellitus
- Interventions
- Disease Surveillance, Family Studies, Questionnaire Followup
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1992 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neuroblastoma
- Interventions
- SF1126
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Characteristics of Dermatologists Who Focus on Ethnic Skin
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Parkinson Disease
- Interventions
- Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 18
- States / cities
- Sunnyvale, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
- Conditions
- Epilepsy, Localization-related Epilepsy, Infantile Spasms, Lennox-Gastaut Syndrome, Polymicrogyria, Periventricular Heterotopias
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 4 Weeks to 60 Years
- Enrollment
- 4,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 19 more
- Conditions
- Character, Violence, Substance Use, Pro-social Behavior, Academic Achievement
- Interventions
- Positive Action
- Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2006
- U.S. locations
- 3
- States / cities
- Twin Falls, Idaho • Chicago, Illinois • Corvallis, Oregon
- Conditions
- Advanced Solid Tumors
- Interventions
- axitinib, crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 15
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more
- Conditions
- Cardiac Rhythm Disorder
- Interventions
- Not listed
- Lead sponsor
- Medtronic
- Industry
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 118
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 115 more
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Biological · Drug
- Lead sponsor
- Reem Karmali
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
- Interventions
- Guanfacine Hydrochloride Immediate Release, Placebo
- Drug
- Lead sponsor
- Rachel G. Greenberg, MD, MB, MHS
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
- Conditions
- Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
- Interventions
- UB-VV111, rapamycin
- Genetic · Drug
- Lead sponsor
- Umoja Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Duarte, California • Chicago, Illinois • Grand Rapids, Michigan + 4 more
- Conditions
- Primary Myelofibrosis, MPN-associated Myelofibrosis
- Interventions
- Pomalidomide 0.5 mg, Placebo, Pomalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
- Conditions
- Lung Cancer
- Interventions
- chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
- Genetic · Other · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 405
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
- Conditions
- Huntington's Disease
- Interventions
- coenzyme Q10, placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 31
- States / cities
- San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
- Conditions
- Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
- Interventions
- safusidenib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 39 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Obesity
- Interventions
- IDEAL2 Intervention
- Behavioral
- Lead sponsor
- Etan Orgel
- Other
- Eligibility
- 7 Years to 25 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 13 more